Table 2. Progression criteria for the JAKPPPOT trial.

Domain	Non-feasible	Intermediate	Feasible
Recruitment: proportion of potential participants identified who enrolled in the trial	<20%	20–40%	>40%
Adherence: proportion of participants achieving ‘Good’ adherence (>80% of medication taken as prescribed)	<20%	20–80%	>80%
Acceptability: proportion of participants who view JAK inhibitor therapy in PPP to be ‘acceptable’	<20%	20–80%	>80%

JAK, Janus kinase; JAKPPPOT, Janus kinase inhibitors in palmoplantar pustulosis: a mixed-methods feasibility; PPP, palmoplantar pustulosis.